Fenoy Albert J, Quevedo Joao, Soares Jair C
Department of Neurosurgery, McGovern Medical School, The University of Texas Health Science Center at Houston (UT Health), Houston, TX, USA.
Faillace Department of Psychiatry and Behavioral Sciences, Center of Excellence on Mood Disorders, McGovern Medical School, The University of Texas Health Science Center at Houston, (UT Health), Houston, TX, USA.
Mol Psychiatry. 2022 Jan;27(1):574-592. doi: 10.1038/s41380-021-01100-6. Epub 2021 Apr 26.
The medial forebrain bundle-a white matter pathway projecting from the ventral tegmental area-is a structure that has been under a lot of scrutinies recently due to its implications in the modulation of certain affective disorders such as major depression. In the following, we will discuss major depression in the context of being a disorder dependent on multiple relevant networks, the pathological performance of which is responsible for the manifestation of various symptoms of the disease which extend into emotional, motivational, physiological, and also cognitive domains of daily living. We will focus on the reward system, an evolutionarily conserved pathway whose underperformance leads to anhedonia and lack of motivation, which are key traits in depression. In the field of deep brain stimulation (DBS), different "hypothesis-driven" targets have been chosen as the subject of clinical trials on efficacy in the treatment-resistant depressed patient. The "medial forebrain bundle" is one such target for DBS, and has had remarkably rapid success in alleviating depressive symptoms, improving anhedonia and motivation. We will review what we have learned from pre-clinical animal studies on defining this white matter tract, its connectivity, and the complex molecular (i.e., neurotransmitter) mechanisms by which its modulation exerts its effects. Imaging studies in the form of tractographic depictions have elucidated its presence in the human brain. Such has led to ongoing clinical trials of DBS targeting this pathway to assess efficacy, which is promising yet still lack in sufficient numbers. Ultimately, one must confirm the mechanism of action and validate proof of antidepressant effect in order to have such treatment become mainstream, to promote widespread improvement in the quality of life of suffering patients.
内侧前脑束是一条从腹侧被盖区投射出的白质通路,由于其在调节某些情感障碍(如重度抑郁症)中的作用,该结构最近受到了大量审查。接下来,我们将在重度抑郁症是一种依赖多个相关网络的疾病的背景下进行讨论,这些网络的病理表现导致了该疾病各种症状的显现,这些症状延伸到日常生活的情感、动机、生理以及认知领域。我们将重点关注奖赏系统,这是一条进化上保守的通路,其功能不足会导致快感缺失和缺乏动机,而这正是抑郁症的关键特征。在深部脑刺激(DBS)领域,不同的“假设驱动”靶点已被选为治疗抵抗性抑郁症患者疗效临床试验的对象。“内侧前脑束”就是这样一个DBS靶点,在缓解抑郁症状、改善快感缺失和动机方面取得了显著快速的成功。我们将回顾从临床前动物研究中学到的关于定义这条白质束、其连接性以及其调节发挥作用的复杂分子(即神经递质)机制的知识。以纤维束成像描绘形式进行的影像学研究已经阐明了它在人脑中的存在。这导致了针对该通路的DBS正在进行的临床试验以评估疗效,虽然前景乐观但数量仍然不足。最终,必须确认作用机制并验证抗抑郁效果的证据,以使这种治疗成为主流,从而促进痛苦患者生活质量的广泛改善。